Vericel Corp.

{
  "main_header": {
    "sid": 1162426,
    "name": "Vericel Corp.",
    "stock_name": "Vericel Corp.",
    "full_name": "Vericel Corp.",
    "name_url": "stocks-analysis/vericel-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "35.38",
    "chg": -1.72,
    "chgp": "-4.64%",
    "dir": -1,
    "prev_price": "37.10",
    "mcapval": "1,907.65",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US92346J1088",
    "curr_date": "Feb 05",
    "curr_time": "",
    "bse_nse_vol": "398.43 k",
    "exc_status": "Active",
    "traded_date": "Feb 05, 2026",
    "traded_date_str": "2026 02 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vericel-corp-1162426-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-shift-from-fair-to-expensive-amid-high-pe-ratio-3686287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VericelCorp_valuationdot_3686287.png",
        "date": "2025-11-10 16:04:34",
        "description": "Vericel Corp., a small-cap biotechnology firm, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a Price to Book Value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers like Madrigal Pharmaceuticals and Cytokinetics."
      }
    ],
    "total": 21,
    "sid": "1162426",
    "stock_news_url": "https://www.marketsmojo.com/news/vericel-corp-1162426"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Metrics

2025-11-10 16:04:34

Vericel Corp., a small-cap biotechnology firm, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a Price to Book Value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers like Madrigal Pharmaceuticals and Cytokinetics.

Read full news article

View All News